Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

A sleep apnea drug is already available in the ... gut receptors to spark metabolic effects, such as weight loss. The way Zepbound works to treat OSA is unknown, but obesity is a risk factor ...

South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But ...

A Boston-based biopharmaceutical company is revolutionizing the weight-loss drug industry. Syntis Bio has created a daily ...

Medicare covers GLP-1s to treat diabetes and some other health conditions, including obstructive sleep apnea and ... access GLP-1s for weight loss. Meanwhile, the Food and Drug Administration ...

This proves that Eli Lilly's obesity drug Zepbound, as a GLP-1/GIP agonist, is far more capable of delivering weight loss compared ... and for obstructive sleep apnea. According to the 10-Q ...

Prediabetes is a clinical inflection point and a modifiable risk state. Small shifts in care can translate to big shifts in ...